According to a new market research report Liquid Biopsy Market by Cancer Type (Lung, Breast, Colorectal, Prostate), Circulating Biomarkers (Circulating Tumor Cells, Circulating Tumor DNA, Cell-Free DNA), Product (Instruments, Assay Kits), End User (Reference Laboratory) - Global Forecast to 2022, published by MarketsandMarkets™, the market is expected to reach USD 2,047.9 Million by 2022 from an estimated USD 715.7 Million in 2017, at a CAGR of 23.4%.
The key factors driving the growth of this market include increasing prevalence of cancer, increasing preference for noninvasive procedures, initiatives undertaken by government and global health organizations, technological advancement to augment market revenues, rising emphasis on personalized medicine, and availability of funding for liquid biopsy RBrowse 133 Market Data Tables and 44 Figures spread through 204 Pages and in-depth TOC on "Liquid Biopsy Market"Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350 By product, the assay kits segment is expected to account for the largest share of the market in 2017On the basis of product, the Liquid Biopsy Market is broadly segmented into assays kits, instruments, and services.
In 2017, the assay kits segment is expected to account for the largest share of this market.
The ability for early assessment of patient prognosis and also providing valuable information to make a clinical decision is driving the growth of the CTC segment in the Liquid Biopsy Market.By clinical application, the therapy selection segment is expected to account for the largest market share in 2017Based on clinical application, the Liquid Biopsy Market is segmented into early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring.
Increasing prevalence of cancer and the growing number of research studies on liquid biopsy for cancer applications is driving the growth of this market.By end user, the reference laboratories segment is expected to account for the largest market share in 2017Based on end user, the Liquid Biopsy Market is segmented into reference laboratories, hospitals and physician laboratories, academic and research centers, and other end users (public health laboratories, pathology laboratories, and small molecular laboratories).
A number of factors such as the easy accessibility and high adoption of advanced diagnostic technologies (such as PCR and NGS) among healthcare professionals, rising prevalence of cancer in the US and Canada, technological advancements in liquid biopsy products, and growing public and private funding to support research activities in the field of liquid biopsy are aiding market growth in the region.Request For Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=13966350 The key players in the global Liquid Biopsy Market are QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories Inc. (US), Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (Italy), Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, Inc. (US), RainDance Technologies, Inc. (US), and MDx Health SA (US).About MarketsandMarkets™MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues.